Document:

Supply Agreement

 Exhibit 10.15 
 ***Text Omitted and Filed Separately 
 with the Securities and Exchange
Commission. 
 Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406 

Index of Contents 
  

							
	1.	  	DEFINITIONS	  	 	1	  
	2.	  	MANUFACTURE AND SALE	  	 	3	  
	3.	  	 EXCLUSIVITY
	  	 	3	  
	4.	  	RIGHT OF FIRST REFUSAL	  	 	4	  
	5.	  	FORECASTS, ORDERS AND DELIVERY	  	 	5	  
	6.	  	PRICES AND PAYMENT	  	 	6	  
	7.	  	REGULATORY RESPONSIBILITY	  	 	7	  
	8.	  	QUALITY CONTROL REQUIREMENTS	  	 	8	  
	9.	  	REJECTION	  	 	9	  
	10.	  	WARRANTY	  	 	10	  
	11.	  	INDEMNIFICATION	  	 	12	  
	12.	  	REPRESENTATIONS	  	 	12	  
	13.	  	TERM AND TERMINATION	  	 	13	  
	14.	  	MISCELLANEOUS	  	 	14	  
	EXHIBIT A: DEVICE SPECIFICATION	  	 	18	  
	EXHIBIT B: SELLER CERTIFICATE OF ANALYSIS + SELLER STANDARD SPECIFICATION	  	 	19	  
	EXHIBIT C: PURCHASE PRICE	  	 	20	  
	EXHIBIT D: EXCLUSIVITY	  	 	23	  
	EXHIBIT E: STANDARD TERMS AND CONDITIONS	  	 	25	  
	EXHIBIT F: STANDARD PACKAGING AND PACKING SPECIFICATIONS	  	 	27	  

  
 i 

 SUPPLY AGREEMENT 

This SUPPLY AGREEMENT (the “Agreement”), effective as of the seventh day of March, 2011 (the “Effective
Date”), is made and entered into by and between Insys Therapeutics, Inc., a Delaware corporation having its principal place of business at 10220 South 51st St., Suite 2, Phoenix, AZ 85044-5231 (hereinafter called
“PURCHASER”) and Aptargroup, Inc., a Delaware corporation having its principal place of business at 475 West Terra Cotta, Suite E, Crystal Lake, IL, 60014-9695 (hereinafter called “SELLER”). PURCHASER and SELLER
being hereinafter called individually the “Party” and collectively the “Parties”. 
 WHEREAS SELLER is engaged
in the development and manufacture of dispensing systems for medical use, with particular reference to nasal and oral devices; 
 WHEREAS
PURCHASER desires to purchase the Device (defined below) for Purchaser’s own use with Drug Product (defined below), subject to the terms and conditions herein; and 
 WHEREAS SELLER desires to sell the Device to PURCHASER subject to the terms and conditions herein. 

NOW, THEREFORE, in consideration of the mutual promises and covenants contained herein, the Parties agree as follows: 

 

	1.	DEFINITIONS 

 As used herein, the
following terms and expressions shall have the meanings set forth below: 
  

	 	1.1	“Affiliate” means any person or entity that directly or indirectly through one or more intermediaries’ Controls, is Controlled by, or is under
common Control with a Party, where “Control” means the direct or indirect, legal or beneficial ownership of more than fifty percent (50%) of the outstanding voting rights in a company. 

 

	 	1.2	“cGMP” means the current good manufacturing practices stipulated or promulgated from time to time by the Regulatory Authorities that are applicable to
the manufacture of the Device. 

  

	 	1.3	“Cumulative Yearly Quantity” means the cumulative total Minimum Yearly Quantity amount of the Device PURCHASER must procure from the SELLER to maintain
pricing levels as defined in Exhibit C. 

  

	 	1.4	“Development Activities” means all research and development activities related to the development of a drug (including alternative delivery systems)
through preclinical and clinical stages. 

  

	 	1.5	“Device” means the device described in the Device Specifications. 

  
 1 

	 	1.6	“Device Equipment” means the moulds and assembly machines required at SELLER’s premises to manufacture the Device in commercial quantities.

  

	 	1.7	“Device Equipment Contribution” means the PURCHASER’s [...***...] reimbursement of research and development costs of SELLER related to, but
not limited to, the Device Equipment as described in Exhibit C. 

  

	 	1.8	“Design” means any combination of outer shape and color of the Device. 

 

	 	1.9	“Device Specifications” means the Device’s specifications as described in Exhibit A. 

 

	 	1.10	“Drug Product” means the sublingual formulation of Fentanyl owned by PURCHASER and currently known as “Fentanyl SL”.

  

	 	1.11	“Effective Date” means the day inserted on the introductory clause of this Agreement. 

 

	 	1.12	“FDA Approval” means the approval of the new drug application (NDA) for the Finished Product by the Food and Drug Administration in the United States
of America (FDA). 

  

	 	1.13	 “Fentanyl” means the compound with molecular formula C22H28
N2O and IUPAC name N-(1-2-phenlyethyl)-4-piperidinyl)-N-phenylpropanamide . 

  

	 	1.14	“Fentanyl Market” means the total unit sales of all non-extended release pharmaceutical products containing Fentanyl as an active pharmaceutical
ingredient. 

  

	 	1.15	“Finished Product” means the Drug Product in conjunction with the Device. 

 

	 	1.16	“Intellectual Property” means all present and future intellectual property rights and information, material and trade secrets that relate to the Device
or the Drug Product, as the case may be, whether or not patentable, including any know-how. 

  

	 	1.17	“Marketing Approval” means, with respect to any country, the approval of any marketing application for the Finished Product by the appropriate
Regulatory Authority in such country, including (a) FDA Approval, (b) approval of a marketing authorization application by the EU Medicines Agency and (c) approval of other product registration application with respect to any other
territory. 

  

	 	1.18	“Minimum Yearly Quantity” means the minimum amount of the Device PURCHASER must procure from the SELLER per year as defined in Exhibit C.

  

	 	1.19	“Purchase Price” shall have the meaning set forth in Exhibit C. 

 

	 	1.20	“Regulatory Authority” or “Regulatory Authorities” means the United States Food and Drug Administration and any divisions thereof, any
equivalent agency of any other country and any division thereof, and any other applicable regulatory body. 

  

					
		  	2	  	***Confidential Treatment Requested

	 	1.21	“Success Fee” means the fee to be paid by PURCHASER to SELLER as specified in Exhibit D upon successful FDA Approval. 

 

	2.	MANUFACTURE AND SALE 

  

	 	2.1	Supply and Purchase Obligations. SELLER agrees to manufacture and sell to PURCHASER, and PURCHASER agrees to purchase from SELLER, such quantities of the Device
as PURCHASER may order from SELLER in accordance with the terms and conditions of this Agreement. 

  

	 	2.2	Device Equipment. Seller will utilize Device Equipment for the manufacture of the Device. Ownership of Device Equipment shall remain with SELLER. In case
PURCHASER wants to obtain ownership of Device Equipment, it shall purchase from SELLER Device Equipment at a price to be agreed between Parties and pay the applicable German VAT at the time of transfer of ownership. No such purchase shall occur
without SELLER’s prior written consent. In no case shall Device Equipment leave SELLER’s premises. 

  

	 	2.3	cGMP Compliance. SELLER shall assemble and package the Device in accordance with the Device Specifications and applicable cGMP as of the Effective Date.

  

	 	2.4	Intellectual Property. Any Intellectual Property owned or controlled as of the Effective Date by PURCHASER, SELLER, or their Affiliates shall remain the absolute
unencumbered property of SELLER and PURCHASER respectively. SELLER shall own all arising Intellectual Property rights related to the Device. SELLER reserves the right to prosecute, maintain and defend SELLER’s Intellectual Property, at
SELLER’s discretion and expense. SELLER’s IP is broadly drafted and includes trade secrets and patents related to the Device. SELLER may have strategic reasons to defend or not such IP and will need flexibility to exercise in its own
discretion, particularly any IP that has applications to other SELLER’s products. 

  

	3.	EXCLUSIVITY 

  

	 	3.1	SELLER is willing to supply the Device to PURCHASER on an exclusive basis per the conditions and limitations set forth in Exhibit D. For the
avoidance of doubt, such Exclusivity does not contain any license for patents or technologies. Neither Party grants any licenses to the other party. 

  

	 	3.2	The SELLER agrees to that the PURCHASER has Design exclusivity to the Device. 

 

	 	3.3	 The exclusivity rights granted to PURCHASER hereunder shall be valid for the duration of the Exclusivity Term (as defined in Exhibit D);
provided, that, if the exclusivity provisions in this Agreement are challenged by a third party or any governmental authority, PURCHASER shall, at SELLER’s option, either (i) defend, indemnify and hold harmless the SELLER, its
Affiliates and their directors, officers, 

  

					
		  	3	  	

	 	
employees and agents from and against any losses suffered or resulting from such challenge, or (ii) convert the exclusive rights herein to non-exclusive rights. 

 

	4.	RIGHT OF FIRST REFUSAL 

  

	 	4.1	Grant of Right of First Refusal. PURCHASER hereby grants SELLER the exclusive option (but not the obligation) to supply to PURCHASER all of its requirements of a
Drug Delivery System (as defined below) for any Alternate Route of Administration (as defined below) in accordance with the terms of this Article 4. For the avoidance of doubt, PURCHASER may not purchase from a Third Party, or develop and
manufacture internally, a Drug Delivery System for any Alternate Route of Administration, unless (a) SELLER does not exercise its right of first refusal in accordance with Section 4.4 or (b) the feasibility study referred to in
Section 4.5 below is not successful unless (c) PURCHASER is engaged in active development of such Drug Delivery System prior to the Effective Date. 

 

	 	4.2	Alternate Route of Administration Drug Development. PURCHASER agrees to notify SELLER in accordance with Section 4.4 about all Development Activities of any
“Alternate Route of Administration” for a new drug that occur after the Effective Date. “Alternate Route of Administration” means any route of administration for a drug including, but not limited to the current sublingual
route of administration, intranasal, pulmonary, buccal, topical, ophthalmic, and otic drug delivery but excluding oral solid dosing. 

  

	 	4.3	Alternate Route of Administration Drug Delivery Systems. PURCHASER agrees to notify SELLER about all Development Activities that would utilize any “Drug
Delivery System” for any Alternate Route of Administration. “Drug Delivery Systems” used for Alternate Route of Administration includes but are not limited to all forms of spray devices, metered pumps, metered valves,
continuous valves, dry powder inhalers, unit and bi dose devices, and dispensing closures. 

  

	 	4.4	 Exercise of Right of First Refusal. PURCHASER shall deliver a written notice informing the SELLER of any Development Activities for a new drug
involving an Alternate Route of Administration within [...***...] of starting any such activities, which notice shall include information describing such Development Activities and specify whether any Drug Delivery System is preferred or is
then being researched or assessed. Within [...***...] following SELLER’s receipt of such notice, SELLER shall notify PURCHASER of its intention to exercise the right of first refusal set forth in Section 4.1. If SELLER decides to
exercise such right, then (a) PURCHASER shall provide to SELLER all information related to the applicable Development Activities relevant for the design or manufacture of the Drug Delivery System and (b) SELLER shall have [...***...]
from the date all necessary information and materials are provided by PURCHASER to present a Drug Delivery 

  

					
		  	4	  	***Confidential Treatment Requested

 
System for such Alternate Route of Administration to the PURCHASER, but in no event later than [...***...] from the date of SELLER’s notice unless PURCHASER is responsible for any
delays. 
  

	 	4.5	Feasibility Studies. If SELLER provides to PURCHASER within the allotted time a Drug Delivery System for use with any such Alternate Route of Administration
Development Activities, PURCHASER shall perform a feasibility study with SELLER’s Drug Delivery System in accordance with the terms of a feasibility agreement to be negotiated by the Parties in good faith. If such feasibility study is
successful (as defined in the feasibility agreement), PURCHASER will be required to move forward with SELLER’s Drug Delivery System and the Parties shall then negotiate a supply agreement under terms similar to this Agreement. If the
feasibility study is unsuccessful, PURCHASER is free to seek alternate partners for such Drug Delivery System. 

  

	5.	FORECASTS, ORDERS AND DELIVERY 

  

	 	5.1	Estimates and Forecasts. Prior to FDA Approval and upon SELLER’s request, beginning on the first day of each calendar quarter, PURCHASER shall provide
SELLER a non-binding written rolling estimate of purchases of the Device for the [...***...] following the calendar quarter in which such estimate is submitted (the “Estimate”). The Estimate shall specify the desired delivery
dates for each month submitted. PURCHASER shall use its best efforts to assure that each Estimate is accurate, provided however, that the Parties agree that such Estimate shall not constitute an obligation of PURCHASER to purchase the estimated
quantities contained in the Estimate. 

 Following FDA Approval, on the first day of each calendar quarter,
PURCHASER shall provide SELLER a written rolling forecast of purchases of the Device for the [...***...] following the calendar quarter in which such forecast is submitted (the “Forecast”). The Forecast shall specify the
desired delivery dates for each month submitted. PURCHASER shall use its best efforts to assure that each Forecast is accurate, provided however, that the Parties agree that such Forecast (other than the quantities set forth in the Purchase Order)
shall not constitute an obligation of PURCHASER to purchase the estimated quantities contained in the Forecast and that SELLER may charge PURCHASER for otherwise un-reimbursed charges incurred due to reasonable commitments made by SELLER to
suppliers based on such Forecast. PURCHASER agrees that the first [...***...] of each Forecast shall be a firm purchase order of the Device by PURCHASER for which SELLER is authorized to commence production, and which PURCHASER shall purchase
(the “Purchase Order”). 
  

	 	5.2	 Delivery. SELLER shall manufacture, package and deliver ordered quantities of the Device as long as such orders are within the scope of
confirmed Purchase Orders. SELLER shall promptly notify PURCHASER if it will be unable to deliver any part of an order exceeding the quantities set forth on the confirmation of the Purchase Order. SELLER shall not be obligated to supply in any month
any quantity of the 

  

					
		  	5	  	***Confidential Treatment Requested

	 	
Device exceeding [...***...] of the Purchase Order, and PURCHASER shall purchase at least [...***...] of the quantities set forth in the Purchase Order. SELLER will use its reasonable
commercial efforts to deliver the Device within the time schedule set forth in the confirmation of the Purchase Order. 

  

	 	5.3	Terms of Delivery. Unless otherwise specified in the Purchase Order, SELLER of the Device to PURCHASER shall be via truck, and shall be delivered EXW Congers, NY
manufacturing site (INCOTERMS 2010) to the place of destination in the United States of America named in the Purchase Order. In the event PURCHASER requests SELLER to transport the Device to PURCHASER via air, PURCHASER shall bear all additional
costs of such air transportation. SELLER shall arrange for transportation of the Device by insured common carrier, or SELLER’s truck to PURCHASER’s specified plant or other designated destination in the United States of America. In the
event PURCHASER requires delivery to destination outside the United States of America, new delivery terms shall be negotiated. The Purchase Price for the Device is based on EXW Congers, NY manufacturing site (INCOTERMS 2010). If the Device is
manufactured outside the United States, SELLER and PURCHASER shall negotiate in good faith to agree on appropriate terms. 

  

	 	5.4	Shipment. SELLER shall ship the Device in multiples of full production lots, as defined in Exhibit C. SELLER shall deliver with each lot a Certificate of
Analysis substantially in the form attached hereto as Exhibit B. 

  

	6.	PRICES AND PAYMENT 

  

	 	6.1	Purchase Price. The Purchase Price for the Device is set forth in Exhibit C. 

 

	 	6.2	Payment for the Device. Payment related to the Device shall be made in full within [...***...] of the date of SELLER’s invoice. SELLER shall date and
send invoices for the Device upon shipment of the Device. 

  

	 	6.3	Taxes. The Purchase Price for the Device does not include any property, license, privilege, sales, service, use, excise, value added, gross receipts, or other
like taxes. PURCHASER agrees to pay or reimburse SELLER for any such taxes that SELLER is required to pay or collect or that are required to be withheld. 

  

	 	6.4	[...***...]. 

  

	 	6.5	Device Equipment Contribution. PURCHASER shall pay the Device Equipment Contribution within [...***...] of the date of the SELLER’s invoice. SELLER
shall date and send invoices upon the milestones defined in Exhibit C. 

  

	 	6.6	Currency. All payments hereunder shall be made in United States Dollars (USD). 

  

					
		  	6	  	***Confidential Treatment Requested

	 	6.7	Interest. If PURCHASER fails to pay the full invoiced amount for the Device, or any part thereof, within [...***...] after the due date, SELLER shall be
entitled (without prejudice to any other right or remedy it may have whether under the terms of this Agreement or otherwise) to charge, in addition to any monies due hereunder, interest on the outstanding amount at the rate of [...***...] or
the highest applicable rate allowed by law, whichever is less, calculated on a daily basis from such date until the date actual payment is made 

  

	 	6.8	Price Revision Due to Changes in Device Specifications. 

  

	 	6.8.1	By PURCHASER. 

 PURCHASER may
request a change, in writing, to the Device Specifications, the manufacturing procedures or control procedures. SELLER will use commercially reasonable efforts to implement the change subject to pricing adjustments, which will be negotiated in good
faith by SELLER and PURCHASER. 
  

	 	6.8.2	By SELLER. 

 SELLER will notify
PURCHASER in writing prior to implementing any change affecting the chemical, biological or physical aspects of the Device. SELLER will not make any changes to the Device Specifications without PURCHASER’s prior written consent shall not be
unreasonably withheld or delayed. SELLER will implement the change subject to pricing adjustments, which will be negotiated in good faith by SELLER and PURCHASER. 
  

	 	6.8.3	By Regulatory Authorities. 

 In
the event of changes required by cGMP’s or other applicable laws or regulations, or in the requirements for the Device, whether written or un-written, by the Regulatory Authorities, SELLER shall have the right to adjust the Purchase Price, such
adjustment being negotiated in good faith by SELLER and PURCHASER. 
  

	7.	REGULATORY RESPONSIBILITY 

  

	 	7.1	Regulatory Responsibility. SELLER shall be responsible, at its sole expense, for complying with applicable regulatory requirements relating to the manufacture of
the Device as applicable in SELLER’ s facilities where the Device is manufactured and, shall use commercially reasonable efforts to perform all of its responsibilities and obligations, including applicable design, development, manufacture,
testing, quality control and documentation activities relating to the Device under or contemplated by this Agreement substantially in accordance with all relevant quality standards that must be met to secure regulatory approval worldwide.

 PURCHASER shall be responsible, at its sole expense, for complying with all other applicable regulatory
requirements relating to the use and sale or resale of the Finished Product. 

  

					
		  	7	  	***Confidential Treatment Requested

	 	7.2	Import and Export Laws. PURCHASER shall comply, at its sole expense, with all export and import regulations and laws necessary to export and import components of
the Device to and from PURCHASER’s premises, including without limitation, procuring and maintaining all import and export licenses necessary to ship from the point of manufacture to PURCHASER’ s premises in accordance herewith and the
payment of all duties, tariffs, surcharges and other customs and other governmental fees levied in connection with the exportation and importation of components of the Device from SELLER to PURCHASER’s premises, or such other location as
designated by PURCHASER. 

  

	8.	QUALITY CONTROL REQUIREMENTS 

  

	 	8.1	Quality 

  

	 	8.1.1	The Parties shall agree upon reasonable release tests to be performed by SELLER prior to shipment of the Device in accordance with applicable regulatory requirements
and subject to pricing conditions. Results of such testing will be supplied in the Certificate of Analysis with each shipment as seen in Exhibit B. 

  

	 	8.1.2	PURCHASER shall send prior written notice of any change requested to be made to Drug Product being delivered by the Device that PURCHASER suspects may affect the Device
Specifications. 

  

	 	8.1.3	Notwithstanding any provision to the contrary in this Agreement, SELLER shall not assign or otherwise delegate any of its obligations to ensure the Device’s
quality or compliance with Device Specifications to any third party other than an Affiliate without consent from the PURCHASER. 

  

	 	8.2	PURCHASER’s Inspections. 

  

	 	8.2.1	The Device shall be subjected to a quality control inspection by PURCHASER in accordance with the Device Specifications set forth in Exhibit A, within
[...***...] as from delivery of the Device to the location designated by PURCHASER in the applicable Purchase Order. 

  

	 	8.2.2	Upon reasonable prior notice, SELLER shall permit PURCHASER to review SELLER’ s quality control procedures and records related to the Device for the purpose of
assuring satisfactory compliance with the Device Specifications and compliance with the provisions of the Quality Agreement. That review shall be conducted in a reasonable manner, during SELLER’s business hours, in the presence of a SELLER
representative and at PURCHASER’s own expense. 

  

	 	8.2.3	 Upon reasonable prior notice, SELLER may permit PURCHASER’s quality assurance personnel to visit SELLER’s production facility, to the extent
that such visit is reasonably required to assure compliance with regulatory requirements or to the extent a review of records alone is not adequate to 

  

					
		  	8	  	***Confidential Treatment Requested

	 	
assure satisfaction with such quality control requirements. Such visit shall be conducted in a reasonable manner, during SELLER’s business hours, in the presence of a SELLER representative,
at PURCHASER’s own expense and shall be limited to the equipment, records or production actually used in the manufacture of the Device. 

  

	 	8.2.4	SELLER shall (i) participate and cooperate with PURCHASER’s personnel who may visit SELLER’s production facility as provided in this Section 8,
(ii) take corrective action in a timely manner as may be reasonably required by PURCHASER to comply with the provisions of this Agreement and with cGMP requirements when applicable, subject to pricing conditions in Sections 4 and Exhibit
C, and (iii) when requested by PURCHASER, describe in writing, any appropriate corrective action planned or taken. 

  

	 	8.3	Regulatory Inspections. 

  

	 	8.3.1	In the event that any of SELLER’s products, facilities and/or processes that are used for the manufacture of the Device are the subject of an inspection related to
PURCHASER by any Regulatory Authority or any other duly authorized agency of any national, state, or local government, SELLER shall promptly notify PURCHASER of such inspection and shall supply PURCHASER with copies of any correspondence or portions
of correspondence that relate to the Device, as well as SELLER’ s proposed response, if any. 

  

	 	8.3.2	In the event that any of PURCHASER’s facilities that are used for the storage of the Device or the manufacturing of the Finished Product are the subject of an
inspection by any Regulatory Authority or any other duly authorized agency of any national, state, or local government, PURCHASER shall promptly notify SELLER of such inspection and shall supply SELLER with copies of any correspondence or portions
of correspondence that relate to the Device, as well as PURCHASER’s proposed response, if any. 

  

	 	8.3.3	In the event that either Party receives any written communications from any Regulatory Authority in connection with the manufacture, use, or sale of the Device for
PURCHASER, it shall provide the other Party with a copy of each such communication and the proposed response, if any. 

  

	 	8.3.4	Records. SELLER shall retain samples of the Device, batch and other manufacturing and analytical records, records of shipments of the Device and validation data
relating to the Device for a minimum of [...***...] and shall make such data available to PURCHASER and Regulatory Authorities upon PURCHASER’s reasonable request or if required by law. 

 

	9.	REJECTION 

  

	 	9.1	 General. In the event that any portion of the Device delivered to PURCHASER by SELLER shall fail to conform with the Device Specifications,
PURCHASER may 

  

					
		  	9	  	***Confidential Treatment Requested

	 	
reject that portion by giving written notice within [...***...] following receipt of Products and sending, at SELLER’s expense, the defective samples to SELLER after SELLER’s
acceptance of rejection. Failure to report claim within that period, PURCHASER shall be considered as having accepted delivery and SELLER shall not be held liable with respect to the defective Device. 

 

	 	9.2	Unattributed Defects. In case the Device does not comply with the Device Specifications due to hidden or latent defects that were not noticeable at the time of
inspection by PURCHASER pursuant to Section 8.2, PURCHASER shall immediately inform SELLER of its claims in this respect, at the latest within the later period of [...***...] following the discovery of the defect or any third party or
regulatory claim or liability arising from the defect. Failing any claims within [...***...] in this respect, it shall not be possible to engage SELLER’s liability. Notwithstanding the foregoing, SELLER shall not be liable for any defect
appearing more than [...***...] after the Device (stored and handled in accordance with commercially reasonable standards) is received at PURCHASER’s premises. 

 

	 	9.3	Claims. Any and all claims shall be substantiated and explained in reasonable detail as to the nature of the defects or failure of the Device to comply with the
Device Specifications. PURCHASER shall reasonably provide SELLER with any and all substantiation regarding the reality of the anomalies recorded, notably with defective samples and shall ensure that SELLER has reasonable means of confirming the
existence of such anomalies. 

  

	 	9.4	Rejected Device. If PURCHASER rejects the Device in accordance with this Section 9, and after SELLER’s formal acceptance of such rejection, then, at
SELLER’s expense and discretion, PURCHASER shall return to SELLER any such shipment, or any part thereof, that does not comply with the Device Specifications, and receive in exchange therefore at the option of PURCHASER or SELLER, either
(i) a complete refund of the Purchase Price, taxes paid and not recoverable, and shipping costs associated with the Device in form of a credit note, or (ii) fully compliant replacement Device. If the Parties so agree, PURCHASER shall
destroy any non-conforming Device, at SELLER’s expense and in accordance with all applicable legal requirements. While SELLER is investigating the rejection, payments of purchased goods subject to such rejection shall be put on hold until claim
response is given. 

  

	 	9.5	Disputes. If SELLER disputes PURCHASER’s rejection, the Parties shall submit samples of the rejected Device to a mutually acceptable independent laboratory
for analysis, whose decision in the matter shall be final and binding. The costs of such analysis shall be borne by SELLER unless such analysis shows that the Device conforms to the Device Specifications, in which case PURCHASER shall bear the cost
of such analysis. 

  

	10.	WARRANTY 

  

	 	10.1	SELLER’s Warranty. 

  

					
		  	10	  	***Confidential Treatment Requested

	 	10.1.1	SELLER warrants to PURCHASER that the Device, at the time of delivery to PURCHASER as provided in Section 5.2, will conform in all respects to the Device
Specifications. 

  

	 	10.1.2	SELLER does not warrant that the Device may be suitable for the manufacture of any intermediate or finished product (including the Finished Product).

  

	 	10.1.3	It is the exclusive responsibility of PURCHASER to ensure that (i) the Device shipped from SELLER according to the Device Specifications is adapted to the use
which it is intended for, (ii) that the Device Specifications are adapted to the storage of the Device, (iii) that the Device is compatible with the Drug Product, and (iv) that the Drug Product and the Finished Product (other than the
Device) comply with all applicable laws. 

  

	 	10.1.4	SELLER may, but is not required to, perform tests for compatibility between the Device and the Drug Product. SELLER MAKES NO REPRESENTATION OR WARRANTY THAT ANY TESTS
PERFORMED BY OR ON BEHALF OF SELLER ARE ADEQUATE OR SUFFICIENT FOR PURCHASER’S PURPOSES. PURCHASER AGREES NOT TO HOLD SELLER RESPONSIBLE FOR THE ADEQUACY OR SUFFICIENCY OF SUCH TESTS, OR THE RESULTS DERIVED FROM SUCH TESTS.

  

	 	10.2	Exclusions. The warranty provided under Section 10.1(a) shall not apply to any Device that (i) has been tampered with or otherwise altered by
PURCHASER, its Affiliates or their customers, distributors agents; (ii) has been subjected to misuse, negligence, malice or accident by PURCHASER, its Affiliates or their customers, distributors agents; or (iii) has been stored, handled or
used by PURCHASER, its Affiliates or their customers, distributors agents in a manner contrary to the Device Specifications and the Device Specifications or SELLER’s written instructions which can, among others, define maximum periods for the
use of the Device. 

  

	 	10.3	Limitations on Warranty. THE FOREGOING WARRANTIES ARE EXCLUSIVE AND IN LIEU OF ALL OTHER WARRANTIES OF QUALITY AND PERFORMANCE, WRITTEN, ORAL OR IMPLIED, AND ALL
OTHER WARRANTIES, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT, ARE HEREBY DISCLAIMED BY SELLER. 

 

	 	10.4	LIMITATION OF LIABILITY 

  

	 	10.4.1	 No Consequential Damages. IN NO EVENT SHALL SELLER BE LIABLE FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, whether in warranty,
contract, negligence, tort, strict liability, or otherwise including, but not limited to, loss of profits or revenue, delays, or 

  

					
		  	11	  	***Confidential Treatment Requested

	 	
claims of customers of PURCHASER or its Affiliates or other third parties for such or other damages. This limitation of liability shall not apply to claims of liability for death or personal
injury caused by SELLER’s gross negligence, willful act, or omission. 

  

	 	10.4.2	Limitation of Liability. Each Party’s cumulative liability to the other Party for all claims relating to the Device and this Agreement, including any cause
of action based on any theory of contract, tort, or strict liability, shall not exceed One Million US Dollars ($1,000,000). This limitation of liability shall not apply to claims of liability for death or personal injury caused by either
Party’s gross negligence, willful act, or omission. In this respect, PURCHASER expressly undertakes to inform all of its customers, Affiliates or other third parties of the conditions and maximum periods defined for the use of the Device, by
any appropriate means making it possible to inform the said customers, Affiliates or other third parties, prior to use of the Device. 

  

	11.	INDEMNIFICATION 

  

	 	11.1	SELLER. Subject to the liability limitations set forth in clause 10.4, SELLER shall defend, indemnify and hold PURCHASER and its Affiliates, and their
shareholders, directors, officers, employees and agents harmless from and against any and all liability, loss, damage, recalls, causes of action, suits, claims, demands, settlements, costs and expenses or judgments arising from injury or death to
persons or damage to property, of any nature whatsoever, resulting from the failure of the Device to conform to the warranty set forth under Section 10.1, provided that PURCHASER shall have given prompt notice in writing to SELLER of any such
claim. 

  

	 	11.2	PURCHASER. PURCHASER shall defend, indemnify and hold SELLER and its Affiliates, their shareholders, directors, officers, employees and agents harmless from and
against any and all liability, loss, damage, expense, causes of action, suits, claims, demands, settlements, costs and expenses or judgments of any nature whatsoever, resulting from the Finished Product or its marketing, sale, clinical testing,
clinical use or other use or misuse, including any defect, failure to warn or other Device liability claims, except to the extent SELLER is required to indemnify PURCHASER under Section 10.1 of this Agreement, provided that SELLER shall have
given prompt notice in writing to PURCHASER of any such claim. 

  

	 	11.3	Insurance. Each of SELLER and PURCHASER will use its best efforts, by itself or through its Affiliates’ group insurance policies and at its sole cost and
expense, to procure and maintain adequate General & Products Liability Insurance. In addition, SELLER will use its best efforts, by itself or through its Affiliates’ group insurance policies and at its sole cost and expense, to procure
and maintain adequate Property All Risks Insurance in order to cover the value of the Device Equipment and any components thereof in SELLER’s possession or for which SELLER bears the risk of loss. 

 

	12.	REPRESENTATIONS 

  

					
		  	12	  	***Confidential Treatment Requested

	 	12.1	Each Party hereby represents and warrants that it has the full power and authority to enter into and perform this Agreement, and each Party knows of no contract,
agreement, promise, undertaking or other fact or circumstance that would prevent the full execution and performance of this Agreement. 

  

	13.	TERM AND TERMINATION 

  

	 	13.1	Term. This Agreement shall, unless otherwise terminated, remain in full force and effect for a period of five (5) years from the Effective Date (the
“Initial Term”), at which time, the Parties shall discuss in good faith negotiations an extension of this Agreement. 

  

	 	13.2	Early Termination. Without prejudice to any other rights it may have hereunder or at law or in equity, either Party may terminate this Agreement:

  

	 	13.2.1	immediately if the other Party makes an assignment for the benefit of its creditors or a receiver or custodian is appointed for it or its business is placed under
attachment, garnishment or other process involving a significant portion of its business; 

  

	 	13.2.2	after [...***...] written notice from the terminating Party specifying an alleged material breach (including payment breach) and stating its intent to so
terminate, if the other Party fails to commence and diligently pursue to remedy any such material breach of this Agreement; 

  

	 	13.2.3	immediately if the other Party becomes insolvent, an order for relief is entered against the other Party under any bankruptcy or insolvency laws or laws of similar
import; or 

  

	 	13.2.4	upon [...***...] written notice from the terminating Party if the Device does not receive FDA Approval by January 1, 2013. 

 

	 	13.3	Effect of Termination. Neither termination nor non-renewal of this Agreement shall release either Party from fulfilling any obligations it may have incurred
prior to any such termination, nor prejudice any other rights or remedies that either Party may have at law or in equity. 

 In case of early termination by PURCHASER not due to a breach by SELLER, PURCHASER will compensate SELLER for any costs directly related to the value of the goods or components already incurred by SELLER
on the basis of the Purchase Orders received from PURCHASER according to Section 5.1 above. PURCHASER will also compensate SELLER for any costs associated with stock at SELLER’s or at SELLER’s sub suppliers, including, but not limited
to, rubber stoppers, glass vials, and steel needles; provided SELLER and SELLER’s sub suppliers shall be obligated to take all commercially reasonable measures to mitigate the damages resulting from such remaining inventory. 

  

					
		  	13	  	***Confidential Treatment Requested

	 	13.4	Surviving Clauses. Notwithstanding any such termination, any provision set forth in this Agreement remaining to be performed in whole or in part, capable of
taking effect following termination, or which by its nature is contemplated to survive the termination of this Agreement shall survive and continue in full force and effect despite termination. 

 

	14.	MISCELLANEOUS 

  

	 	14.1	Notices. All notices, requests, demands, waivers, consents, approvals or other communications to any Party hereunder shall be in writing and shall be deemed to
have been duly given if delivered personally to such Party or sent to such Party by facsimile transmission, overnight courier or by registered or certified mail, postage prepaid, to the addresses set forth below (or to such other address as the
addressee may have specified in notice duly given to the sender as provided herein): 

 If to SELLER:

 AptarGroup, Inc. 
 475 West Terra Cotta, Suite E 
 Crystal Lake, IL 60014-9695 USA 

Attn: Chief Operating Officer 
 Phone No.: (815) 477 -0424 
 Fax No.: (815) 477-0481 

With cc to: 

Aptar Congers, a division of AptarGroup, Inc. 
 250 North Route 303 
 Congers, NJ 10920-1408 USA 

Attn: President, Aptar Pharma North America 
 Phone No.: (845) 639-3700 
 Fax No: (845) 639-3900 

If to PURCHASER: 
 Name: INSYS 
 10220 South 51st Street, Suite 2 

Pheonix, AZ 85044 USA 
 Attn: President 
 Phone No.: (602) 910 2617 x9021 

Fax No.: (602) 910-2627 
 Such notice, request, demand, waiver, consent, approval or other communications will be deemed to have been given as of the date so delivered, sent by facsimile transmission with receipt confirmed, or
[...***...] after so mailed. 
  

	 	14.2	Choice of Law. This Agreement, along with the Schedules and Exhibits attached, incorporated and referenced herein and all Purchase Orders issued hereunder shall
be governed and interpreted, and all rights and obligations of the Parties shall be determined, in accordance to the laws of the State of New York. 

  

					
		  	14	  	***Confidential Treatment Requested

	 	14.3	Force Majeure. Neither Party shall be responsible or liable in any way for failure or delay in carrying out the terms of this Agreement resulting from any cause
or circumstance beyond that Party’s reasonable control, including, but not limited to, fire, flood, other natural disasters, war, labor difficulties, interruption of transit, accident, explosion, civil commotion, and acts of any governmental
authority; nor shall SELLER be responsible or liable in any way for failure or delay in carrying out the terms of this Agreement if due to any shortage or inability to obtain any raw materials (including energy), equipment or transportation;
provided, in each case, that the affected Party shall give prompt notice thereof to the other Party. No such failure or delay shall terminate this Agreement, and each Party shall complete its obligations hereunder as promptly as reasonably
practicable following cessation of the cause or circumstances of such failure or delay; provided, that if any of the above conditions continues to exist for more than [...***...] after the date of any notice given with regard thereto, either
Party may terminate this Agreement forthwith upon notice to the other. 

  

	 	14.4	Severability. In the event that any provision of this Agreement shall be found in any jurisdiction to be in violation of public policy or illegal or
unenforceable at law or in equity, such finding shall in no event invalidate any other provision of this Agreement in that jurisdiction, and this Agreement shall be deemed amended to the minimum extent required to comply with the law of such
jurisdiction, such provision being adjusted rather than voided if possible. 

  

	 	14.5	Entire Agreement. This Agreement, including any Schedules and Exhibits attached, incorporated or referenced herein, the Quality Agreement, and the
confidentiality agreement referenced in Section 14.9 set forth the entire agreement reached between the Parties with respect to the transactions contemplated hereby. This Agreement (including all Schedules and Exhibits) may not be amended or
modified except by written instrument duly executed by the Parties hereto stating that it is an amendment to this Agreement. 

 With the reservation of the specific provisions of this Agreement and of the Quality Agreement, SELLER’ s general conditions of sales, attached as Exhibit E, shall apply to all sales closed in the
framework of this Agreement, to the exclusion of any and all general conditions of purchase which may be communicated by PURCHASER. 
 The terms of this Agreement shall take precedence over the Quality Agreement, the confidentiality agreement referenced in Section 14.9 or the standard terms and conditions set forth in Exhibit E if
there is any conflict between them. 
  

	 	14.6	No Waiver. The failure of either Party hereto to enforce at any time, or for any period of time, any provision of this Agreement shall not be construed as a
waiver of such provision or of the right of such Party thereafter to enforce each and every provision. Any waiver by a Party of any of its rights under this Agreement in one or more instances shall be in a writing signed by such Party and shall not
be construed as constituting a continuing waiver or as a waiver in other instances. 

  

					
		  	15	  	***Confidential Treatment Requested

	 	14.7	Assignment, Binding Effect. Neither Party shall assign this Agreement nor any of its respective rights or obligations hereunder without the prior written consent
of the other Party, which consent will not be unreasonably withheld, except to any Affiliate of the assigning Party or by operation of law or as otherwise permitted hereunder. Any such attempted assignment without such consent shall be void. This
Agreement and the rights herein granted shall be binding upon and shall inure to the benefit of PURCHASER and SELLER and their respective successors and permitted assigns. 

 

	 	14.8	Arbitration. Any dispute, controversy or claim arising out of or in connection with this Agreement, or the breach, termination or invalidity hereof, that the
Parties are unable to resolve between themselves, shall be settled by arbitration in accordance with the Rules of Arbitration of the International Chamber of Commerce, and judgment upon the award rendered by the arbitrator(s) may be entered in any
court having jurisdiction thereof. Such proceedings shall take place in New York, USA, and shall be conducted in English. The decision of the arbitration proceeding shall be final and binding upon the Parties. This clause shall not be construed to
limit the right of either Party to apply to any court of competent jurisdiction for injunctive relief for unauthorized use of confidential information. 

  

	 	14.9	Confidentiality. A separate agreement signed April 16, 2010 relating to confidentiality has been entered into by the Parties and that agreement constitutes
the entire agreement and understanding of the Parties relating to the subject matter of confidentiality and supersedes any previous agreement or understanding between the Parties in relation to such subject matter. 

[Signature page follows]. 

  

					
		  	16	  	

 IN WITNESS WHEREOF, this Agreement has been duly executed and delivered as of the day and year first above
written. 

									
		 		 	
					
		 	/s/ Stephen J. Hagge	 		 		 	/s/ Michael Babich
		 	 APTARGROUP, INC.
 Name: Stephen
J. Hagge
 Title: Exec. V.P. & Chief Operating Officer
	 		 		 	 INSYS THERAPEUTICS, INC.

Name: Michael Babich
 Title: President and
CEO

 [Signature page of Supply Agreement between AptarGroup, Inc. and Insys Therapeutics, Inc.]

  
 17 

 EXHIBIT A: DEVICE SPECIFICATION 

[...***...] 

  

					
		  	18	  	***Confidential Treatment Requested

 EXHIBIT B: SELLER CERTIFICATE OF ANALYSIS + SELLER STANDARD 

SPECIFICATION 
 [...***...] 

  

					
		  	19	  	***Confidential Treatment Requested

 EXHIBIT C: PURCHASE PRICE 
 The purchase price for the Device (“Purchase Price”) is based on the procured annual quantities of the Device in accordance with Table C1 below: 

Table C.1 Device Purchasing Price Levels 
  

					
	 Price Level
	  	 Quantities (pieces)
	  	 Price ([...***...])

	 1
	  	[...***...]	  	$[...***...]
	 2
	  	[...***...]	  	$[...***...]
	 3
	  	[...***...]	  	$[...***...]
	 4
	  	[...***...]	  	$[...***...]
	 5
	  	[...***...]	  	$[...***...]

 Notwithstanding the above, SELLER grants PURCHASER a Purchase Price equal to Price Level [...***...] subject to
PURCHASER’s procurement of the yearly quantity of units of the Device from the SELLER as described below in Table C.2. Year 1 is defined as the time period leading up to FDA Approval and the first year from the date of FDA Approval of the
Finished Product. For this time period a price of $[...***...] will be offered as long as Year 1 Minimum Yearly Quantity is met. Year 2 is defined as the second year from the date following FDA Approval. For this time period a price of
$[...***...] will be offered as long as Year 2 Minimum Yearly Quantity is met. Year 3 is defined as the third year from the date following FDA Approval of the Finished Product. For this time period a price of $[...***...] will be offered
as long as Year 3 Minimum Yearly Quantity is met. Year 4 is defined as the fourth year from the date following FDA Approval of the Finished Product. For this time period a price of $[...***...] will be offered as long as Year 4 Minimum Yearly
Quantity is met. 
 Table C.2 Minimum Yearly Quantities 
  

							
	 Year
	  	 Minimum Yearly

Quantity
	  	Cumulative Yearly
Quantity	  	Price ([...***...])
				
	 1
	  	[...***...]	  	[...***...]	  	$[...***...]
				
	 2
	  	[...***...]	  	[...***...]	  	$[...***...]
				
	 3
	  	[...***...]	  	[...***...]	  	$[...***...]
				
	 4
	  	[...***...]	  	[...***...]	  	$[...***...]

 In case PURCHASER has not met the Minimum Yearly Quantities set forth in Table C.2 for any reason other than for
SELLER’s fault, pricing for the quantities purchased will be adjusted to the appropriate pricing level as outlined in Table C.1 above and a supplemental invoice will be issued for the difference retroactively at the end of Year 1, Year 2, Year
3 and Year 4 and PURCHASER will pay the resulting difference to SELLER. At the end of the then current Year, SELLER shall calculate the Minimum Yearly Quantities based on the quantities of the Device delivered to PURCHASER pursuant to Purchase
Orders placed for such year. At such time, if PURCHASER has not met the Minimum Yearly Quantities, then SELLER shall send an invoice setting forth (i) a calculation of the actual shipped quantities of the Device at the applicable Purchase Price
and (ii) the difference between such due amount and any amounts paid by 

  

					
		  	20	  	***Confidential Treatment Requested

 
PURCHASER as of such date. PURCHASER shall pay such invoiced amount in full within [...***...] of the date of SELLER’s invoice. 

In the event that Purchaser fails to fulfill the Minimum Yearly Quantities for [...***...] and [...***...], SELLER retains the right to
reevaluate the Price Levels as set forth above in Schedule C.1, taking into account the Producer Price Index (“All Other Plastics Product Manufacturing”) from the US Bureau of Labor Statistics. 

The Parties agree to meet in good faith to discuss extension of supply no later than [...***...] prior to the end of the Year 4 as set forth in
this Agreement. SELLER agrees to extend the supply term in one-year increments, beginning Year 5, provided, SELLER and PURCHASER find an agreement on terms and conditions similar to the ones set forth in this Agreement. In particular prices need to
be agreed by SELLER prior to any extension of this Agreement. Year 5 is defined as the fifth year following FDA Approval of the Finished Product. 
 The Parties agree that prices may be adjusted annually based on the Producer Price Index (“All Other Plastics Product Manufacturing”) from the US Bureau of Labor Statistics. 

The lot size for the Device is no less than [...***...] units and no more than [...***...] units. 

The SELLER’s standard packaging and packing specifications are attached in Exhibit F. 

Currency Adjustments. 
 SELLER shall
calculate the impact of such evolution and inform PURCHASER accordingly. For purposes of clarity, this mechanism is designed for the parties to share the risk of currency fluctuations. 
 Currency adjustments only apply for products related to the Device made and imported from Europe (“Imported Products”). As of the Effective Date, two (2) components of the device are
imported from Europe. 
 [...***...] 
 [...***...] 
 On [...***...] of each year of this Agreement (the
“Currency Adjustment Date”), the Purchase Price of Imported Products only will be revised to reflect fluctuation of the currency exchange rate between the US Dollar and the Euro, compared to the initial base exchange rate on
December 31st, 2009, which shall be [€1
=US$1.40] (the “Base Rate”). On each Currency Adjustment Date, the average exchange rate of the Euro to the US Dollar shall be calculated since the Effective Date or for the prior twelve (12) months. If such floating average
differs from the Base Rate then in effect by at least [...***...] then, and only then, will the percentage change (positive or negative) to the exchange rate over such twelve (12) month period shall be computed and [...***...] of
such percentage change shall be multiplied by the then current US Price to determine the actual US Price that SELLER will invoice to PURCHASER 

  

					
		  	21	  	***Confidential Treatment Requested

 
for all Devices shipped to PURCHASER for after such Currency Adjustment Date. Examples of the calculation of the currency adjustment described herein are set forth below. 

Sample Calculation for Currency Pricing Adjustment 
 1) If the Floating Average Rate as of [...***...] = [...***...], then NO CHANGE ([...***...] è 1.40 < [...***...]). 

2) If the Floating Average Rate as of [...***...] = [...***...], the Price will be adjusted as follows: 

[...***...] 
 Device Equipment
Contribution 
 The Device Equipment Contribution to be paid by PURCHASER to SELLER is US-$ [...***...]. This contribution includes
SELLER’s standard validation process. Any extra work, such as, but not limited to, analytical testing, performance studies or extractable studies, shall be subject to reasonable commercial terms. 

Invoice Milestones for Device Equipment Costs 
  

			
	 First Payment:
	  	US-$[...***...]
	 Milestone: the Effective Date.
	  	
	 Second Payment:
	  	US-$[...***...]
	 Milestone: first available samples of all components out of moulds.
	  	
	 Third payment:
	  	US-$[...***...]
	 Milestone: qualified components within specification.
	  	
	 Fourth payment:
	  	US-$[...***...]
	 Milestone: Operational Qualification, Installation Qualification, Performance Qualification of assembly
equipment.
	  	

 All prices for Device Equipment are calculated using an exchange rate of 1€ = 1.40 US-$. On any day that any
milestone payment for the Device Equipment is invoiced by SELLER to PURCHASER, the US-$ amount shall be calculated utilizing an exchange rate equal to the final daily exchange rate as published in the Wall Street Journal, or if the Wall Street
Journal ceases to publish an exchange rate, such comparable publication. 

  

					
		  	22	  	***Confidential Treatment Requested

 EXHIBIT D: EXCLUSIVITY 
 SELLER is willing to supply the Device to PURCHASER on an exclusive basis (“Exclusivity”) for the specific application defined below and in accordance with the following terms: 

 

	 	1.	Application, Drug molecule 

 For sublingual/buccal unit dose application of liquid formulations of Fentanyl. 
  

	 	2.	Exclusivity Payments 

Notwithstanding the provisions set forth in Exhibit C or further provisions set forth in this Exhibit D, to retain
the exclusive rights to the Device globally will be as follows. 
 Upon receipt of FDA Approval of the Finished Product, a
Success Fee of [...***...] will be paid by the PURCHASER to the SELLER. The Success Fee will be paid by the PURCHASER in [...***...], with [...***...]. This will grant PURCHASER Exclusivity from the date of NDA submission of the
Finished Product to [...***...] from the date following FDA Approval of the Finished Product, [...***...]. 
 To
maintain Exclusivity in the United States for all subsequent [...***...], an [...***...] purchase and delivery requirement of the Device shall be a minimum of [...***...] (the “Exclusivity Quantity or Exclusive
Quantities”). Commercially available IMS data will be purchased by the PURCHASER and distributed to the SELLER on a [...***...] basis of the non-extended release Fentanyl products. This includes the currently existing non-extended
release Fentanyl products and future launched non-extended release Fentanyl products. To maintain Exclusivity in the rest of the world, PURCHASER, in addition to the purchase of the minimum Exclusive Quantities, must actively seek Marketing Approval
(e.g. public press release, European clinical trials, or public licensing announcements) for the Finished Product in one or more major markets in Europe (e.g. France, Germany and the United Kingdom) within [...***...] of the FDA Approval of
the Finished Product. 
 In the event that the PURCHASER has not purchased the Exclusivity Quantity, Purchaser will pay
shortfall compensation to Seller in the amount of [...***...] of Devices not procured, with payment in full due within [...***...] of notification from SELLER (the “Shortfall Fee”). In the event that Purchaser fails to
fulfill the Exclusivity Quantity requirement for [...***...] consecutive [...***...], SELLER retains the right to terminate any and all Exclusivity terms previously granted to Purchaser and reevaluate the pricing set forth in
Exhibit C of this Agreement. 
  

  

					
		  	23	  	***Confidential Treatment Requested

 The SHORTFALL FEE shall be calculated on [...***...] basis, starting with
[...***...] with the issue of the first purchase order by PURCHASER. If the number of Devices per [...***...] exceeds the Exclusivity Quantity for the previous [...***...], such exceeding quantities shall not be taken into
consideration for the following [...***...]. In no event shall SHORTFALL FEE be due or owing in the event of a failure or inability of Seller to supply the Device during such [...***...] period. 

Exclusivity expires immediately, should regulatory approval be revoked or should the Finished Product be withdrawn from the market in the
US. 
  

	 	3.	Territory 

 To the extent
permitted by applicable law and as otherwise provided herein, the territory of Exclusivity granted by SELLER is valid worldwide. 
  

	 	4.	Timeline 

 Based on
payment of the Success Fee and on the minimum quantities purchased set forth above, Seller is willing to grant Exclusivity to Purchaser commencing upon date of NDA submission of the Finished Product, unless by the date of signature of this contract
SELLER has entered into other obligations with third parties which may be adversely affected by granting such Exclusivity. Exclusivity terms as stated in this Exhibit D are granted until the end of [...***...] or [...***...],
whichever comes first (“Exclusivity Term”). The Parties agree to meet in good faith to discuss extension of Exclusivity no later than [...***...] prior to the end of the Exclusivity term as set forth in this Agreement.

  
 24 

 

 

  
 25 

 

 

  
 26 

 EXHIBIT F: STANDARD PACKAGING AND PACKING SPECIFICATIONS 

 

	1.	Packing 

  

	 	1.1.	Bag Preparation 

  

	 	1.1.1.	[...***...] 

	 	1.1.2.	[...***...] 

	 	1.1.3.	[...***...] 

	 	1.1.4.	[...***...] 

  

	 	1.2.	Carton Sealing 

  

	 	1.2.1.	[...***...] 

  

	 	1.3.	Carton filling/ Pharmaceutical Packaging Area 

  

	 	1.3.1.	[...***...] 

	 	1.3.2.	[...***...] 

	 	1.3.3.	[...***...] 

	 	1.3.4.	[...***...] 

	 	1.3.5.	[...***...] 

  

	 	1.4.	Labeling and closing of carton 

  

	 	1.4.1.	[...***...] 

	 	1.4.2.	[...***...] 

	 	1.4.3.	[...***...] 

	 	1.4.4.	[...***...] 

  

	 	1.5.	Packaging Records 

  

	 	1.5.1.	[...***...] 

  

	 	1.6.	Palletization 

  

	 	1.6.1.	[...***...] 

	 	1.6.2.	[...***...] 

  

	 	1.7.	Shipment preparation 

  

	 	1.7.1.	[...***...] 

  

  

					
		  	27	  	***Confidential Treatment Requested

	 	1.7.2.	[...***...] 

	 	1.7.3.	[...***...] 

	 	1.7.4.	[...***...] 

	 	1.7.5.	[...***...] 

	 	1.7.6.	[...***...] 

	 	1.7.7.	[...***...] 

  

	 	1.8.	Stretch Wrap 

  

	 	1.8.1.	[...***...] 

	 	1.8.2.	[...***...] 

	 	1.8.3.	[...***...] 

  

	 	1.9.	Paperwork 

  

	 	1.9.1.	[...***...] 

	 	1.9.2.	[...***...] 

	 	1.9.3.	[...***...] 

  

	 	1.10.	Bill of Lading 

  

	 	1.10.1.	[...***...] 

	 	1.10.2.	[...***...] 

  

	 	1.11.	Pick up by carrier 

  

	 	1.11.1.	[...***...] 

  

  

					
		  	28	  	***Confidential Treatment Requested

	 	1.11.2.	[...***...] 

	 	1.11.3.	[...***...] 

  

	 	1.12.	Communication of Shipment 

  

	 	1.12.1.	[...***...] 

	 	1.12.2.	[...***...] 

	 	1.12.3.	[...***...] 

  

	 	1.13.	Palletization of Finished Products: 

  

	 	1.13.1.	[...***...] 

	 	1.13.2.	[...***...] 

	 	1.13.3.	[...***...] 

	 	1.13.4.	[...***...] 

	 	1.13.5.	[...***...] 

	 	1.13.6.	[...***...] 

	 	1.13.7.	[...***...] 

	 	1.13.8.	[...***...] 

	 	1.13.9.	[...***...] 

  

					
		  	29	  	***Confidential Treatment RequestedTwenty-Second Supplemental Indenture

 Exhibit 4.1 
 EXECUTION VERSION 
  
  

 
 ANHEUSER-BUSCH INBEV WORLDWIDE
INC. 
 and 
 ANHEUSER-BUSCH INBEV SA/NV 
 and 

the SUBSIDIARY GUARANTORS party hereto from time to time 
 and 
 THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. 

Trustee 
  

 
 TWENTY-SECOND SUPPLEMENTAL
INDENTURE 
 Dated as of July 14, 2011 
  

 
 To the Indenture, dated as of
October 16, 2009, 
 among Anheuser-Busch InBev Worldwide Inc., 

Anheuser-Busch InBev NV/SA, the Subsidiary Guarantors party thereto from time to 

time and 
 The Bank
of New York Mellon Trust Company, N.A., Trustee 
 Floating Rate Notes due 2014 

 
  

 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
	
	 ARTICLE I

 
 DEFINITIONS AND OTHER PROVISIONS OF GENERAL
APPLICATION
	   
 

  

			
	 SECTION 1.01
	 	 Definitions
	  	 	3	  
	 SECTION 1.02
	 	 Effect of Headings
	  	 	6	  
	 SECTION 1.03
	 	 Separability Clause
	  	 	6	  
	 SECTION 1.04
	 	 Benefits of Instrument
	  	 	6	  
	
	 ARTICLE II

 
 FLOATING RATE NOTES DUE 2014
	   
 

  

			
	 SECTION 2.01
	 	 Creation of Series; Establishment of Form
	  	 	6	  
	 SECTION 2.02
	 	 Guarantee
	  	 	7	  
	 SECTION 2.03
	 	 Interest
	  	 	7	  
	 SECTION 2.04
	 	 Payment of Principal, Interest and Other Amounts
	  	 	9	  
	 SECTION 2.05
	 	 Optional Tax Redemption
	  	 	9	  
	 SECTION 2.06
	 	 Additional Covenant
	  	 	10	  
	
	 ARTICLE III

 
 MISCELLANEOUS PROVISIONS
	   
 

  

			
	 SECTION 3.01
	 	 Effectiveness
	  	 	10	  
	 SECTION 3.02
	 	 Original Issue
	  	 	10	  
	 SECTION 3.03
	 	 Ratification and Integral Part
	  	 	10	  
	 SECTION 3.04
	 	 Priority
	  	 	11	  
	 SECTION 3.05
	 	 Successors and Assigns
	  	 	11	  
	 SECTION 3.06
	 	 Counterparts
	  	 	11	  
	 SECTION 3.07
	 	 Guarantee Limitations
	  	 	11	  
	 SECTION 3.08
	 	 The Trustee
	  	 	11	  
	 SECTION 3.09
	 	 Governing Law
	  	 	11	  
		
	 EXHIBIT A
	  	 	A-1	  
	 EXHIBIT B
	  	 	B-1	  

  
 - 2 -

 TWENTY-SECOND SUPPLEMENTAL INDENTURE, dated as of July 14, 2011 (the
“Twenty-Second Supplemental Indenture”), among ANHEUSER-BUSCH INBEV WORLDWIDE INC., a corporation duly organized and existing under the laws of the State of Delaware (the “Company”), ANHEUSER-BUSCH INBEV NV/SA, a
société anonyme duly organized and existing under the laws of the Kingdom of Belgium (the “Parent Guarantor”), ANHEUSER-BUSCH COMPANIES, INC., a corporation duly organized and existing under the laws of the
State of Delaware, BRANDBREW S.A., a public limited liability company organized and existing under Luxembourg law, COBREW NV/SA, a public limited liability company organized and existing under Belgian law (each, a “Subsidiary
Guarantor”, and together with the Parent Guarantor, the “Guarantors”) and The Bank of New York Mellon Trust Company, N.A., as trustee (the “Trustee”) to the Indenture, dated as of October 16, 2009,
among the Company the Guarantors and the Trustee, as amended from time to time (the “Indenture”). 
 RECITALS
OF THE COMPANY AND THE GUARANTORS 
 WHEREAS, the Company, the Guarantors and the Trustee are parties to the Indenture,
which provides for the issuance from time to time of unsecured debt securities of the Company; 
 WHEREAS, Section 901(9)
of the Indenture permits supplements thereto without the consent of Holders of Securities to establish the form or terms of Securities of any series as permitted by Sections 201 and 301 of the Indenture; 

WHEREAS, as contemplated by Section 301 of the Indenture, the Company intends to issue a new series of Securities to be known as the
Company’s “Floating Rate Notes due 2014” (the “Notes”) under the Indenture; 
 WHEREAS, the
Company and the Guarantors have taken all necessary corporate action to authorize the execution and delivery of this Twenty-Second Supplemental Indenture; 
 NOW, THEREFORE, THIS TWENTY-SECOND SUPPLEMENTAL INDENTURE WITNESSETH: 
 For and in
consideration of the premises and the other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Company, the Guarantors and the Trustee mutually agree as follows: 

ARTICLE I 

DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 
 SECTION 1.01 Definitions. 
 Except as otherwise expressly provided
or unless the context otherwise requires, all terms used in this Twenty-Second Supplemental Indenture which are defined in the Indenture shall have the meanings ascribed to them by the Indenture. The following terms used in this Twenty-Second
Supplemental Indenture have the following respective meanings: 
 “2010 Senior Facility
Agreement” means the USD 13 billion senior facilities agreement, dated as of February 26, 2010, as amended from time to time, for the Parent Guarantor and the Company, arranged by Banc of America Securities Limited, Banco Santander,
S.A., Barclays Capital, Deutsche Bank AG, London Branch, Fortis Bank SA/NV, ING Bank N.V., Intesa Sanpaolo S.p.A., J.P. Morgan PLC, Mizuho Corporate Bank, Ltd., The Royal Bank of Scotland plc, Société Générale
Corporate & Investment Banking, the corporate and investment banking division of Société Générale, and The Bank of Tokyo-Mitsubishi UFJ, Ltd. as mandated lead arrangers and bookrunners, and Fortis Bank SA/NV,
acting as agent and issuing bank. 

  
 - 3 -

 “3-Month LIBOR” has the meaning specified in
Section 2.03. 
 “Business Day” means a day on which commercial banks and exchange markets
are open, or not authorized to close, in the City of New York, London and Brussels. 
 “Business Day
Convention” means that if any Interest Payment Date (other than the Stated Maturity or a date fixed for redemption or payment in connection with an acceleration of the Notes) falls on a day that is not a Business Day, that Interest Payment
Date will be postponed to the next succeeding Business Day unless that Business Day is in the next succeeding calendar month, in which case the Interest Payment Date will be the immediately preceding Business Day. 

“Calculation Agent” means The Bank of New York Mellon Trust Company, N.A. 

“Change in Tax Law” has the meaning set forth in Section 2.05(a). 

“Company” has the meaning set forth in the first paragraph of this Twenty-Second Supplemental Indenture.

 “Date of the Prospectus Supplement” means July 7, 2011 which is the date of the final
Prospectus Supplement prepared in connection with the issuance of the Notes and filed with the Securities and Exchange Commission. 
 “Depositary” means The Depository Trust Company, or any successor thereto. 

  
 - 4 -

 “Fifth Supplemental Indenture” means the Fifth Supplemental
Indenture, dated as of November 27, 2009, among the Company, the Guarantors and the Trustee. 

“Global Security” has the meaning set forth in Section 2.01(d). 

“Guarantors” has the meaning set forth in the first paragraph of this Twenty-Second Supplemental
Indenture. 
 “Indenture” has the meaning set forth in the first paragraph of this Twenty-Second
Supplemental Indenture. 
 “Interest Determination Date” means, for each particular Interest
Reset Date (as defined below), the second London Business Day (as defined below) preceding such Interest Reset Date. 
 “Interest Payment Date” has the meaning specified in Section 2.03. 
 “Interest Period” means the period beginning on, and including, an Interest Payment Date and ending on, but not including, the following Interest Payment Date; provided that the first
Interest Period will begin on July 14, 2011, and will end on, but not include, the first Interest Payment Date. 
 “Interest Reset Date” means, for each Interest Period other than the first Interest Period, the first day of such Interest Period, subject to the Business Day Convention. 

“London Business Day” means any week day on which banking or trust institutions in London are not
authorized generally or obligated by law, regulation or executive order to close. 
 “Notes” has
the meaning set forth in the Recitals. 
 “Parent Guarantor” has the meaning set forth in the
first paragraph of this Twenty-Second Supplemental Indenture. 
 “Regular Record Date” means the
fifteenth calendar day immediately preceding the applicable Interest Payment Date, whether or not such day is a Business Day. 
 “Spread” has the meaning specified in Section 2.03. 
 “Stated Maturity” has the meaning specified in Section 2.01(f). 
 “Twenty-Second Supplemental Indenture” has the meaning set forth in the Recitals. 

  
 - 5 -

 “Trustee” has the meaning set forth in the first paragraph
of this Twenty-Second Supplemental Indenture. 
 SECTION 1.02 Effect of Headings. 

The Article and Section headings herein are for convenience only and shall not affect the construction hereof. 

SECTION 1.03 Separability Clause. 
 In case any provision in this Twenty-Second Supplemental Indenture shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be
affected or impaired thereby. 
 SECTION 1.04 Benefits of Instrument. 

Nothing in this Twenty-Second Supplemental Indenture, express or implied, shall give to any Person, other than the parties hereto and
their successors hereunder and the Holders, any benefit or any legal or equitable right, remedy or claim under this Twenty-Second Supplemental Indenture or the Indenture. 
 ARTICLE II 
 FLOATING RATE NOTES DUE 2014 

SECTION 2.01 Creation of Series; Establishment of Form. 
 (a) There is hereby established a new series of Securities under the Indenture entitled “Floating Rate Notes due 2014”. 
 (b) The form of the Notes, including the form of the certificate of authentication, is attached hereto as Exhibit A. 
 (c) The Company shall issue the Notes in an aggregate principal amount of USD 300,000,000. The Company may from time to time, without the consent of the Holders of the Notes, issue additional Notes in
accordance with Sections 301 and 901 of the Indenture. Any such additional Notes subsequently issued shall rank equally and ratably with the Notes in all respects (except for the payment of interest accruing prior to the issue date of such
further Notes or except for the first payment of interest following the issue date of such further Notes), so that such further Notes shall be consolidated and form a single series with the Notes and shall have the same terms as to status,
redemption or otherwise as the Notes. 
 (d) The Notes shall be issued initially in the form of one or more permanent global
securities, without coupons, registered in the name of the Depositary or 

  
 - 6 -

 
a nominee of the Depositary (each, a “Global Security”) and deposited with the Trustee, as custodian for the Depositary. Any proposed transfer of an interest in the Notes shall
consist of a transfer in a Global Security and shall be effected through the book-entry system maintained by the Depositary. 

(e) The Notes shall not have a sinking fund. 
 (f) The stated maturity of the principal of the Notes shall be July 14, 2014 (the “Stated Maturity”). 
 (g) The outstanding principal amount of the Notes shall accrue interest at a rate equal to 3-Month LIBOR, reset quarterly, plus the Spread, as provided in Section 2.03. 

(h) The Notes shall be issued in denominations of USD 1,000 in principal amount and integral multiples of USD 1,000 in excess thereof.

 (i) The Notes shall be subject to both Defeasance and Covenant Defeasance in accordance with the Indenture. 

(j) The Notes shall be senior unsecured obligations of the Company and will rank equally with all other existing and future unsecured and
unsubordinated debt obligations of the Company. 
 SECTION 2.02 Guarantee. Subject to the terms and applicable
limitations set forth in the Indenture and the form of Notes, the Notes shall be jointly and severally, irrevocably, fully and unconditionally guaranteed by the Guarantors as to all payments due on the Notes whether at their Stated Maturity, by
acceleration, redemption, repayment or otherwise in accordance with the terms of such Guarantees and the Indenture. In the case of the failure of the Company to pay punctually any principal, premium or interest on the Notes, the Guarantors shall
cause any such payment to be made as it becomes due and payable, whether at maturity, upon acceleration, redemption, repayment or otherwise. The Guarantees shall be unsecured and unsubordinated indebtedness of the Guarantors and rank equally with
other unsecured and unsubordinated indebtedness of the Guarantors that is currently outstanding or that they may issue in the future. 
 SECTION 2.03 Interest. The Notes shall bear interest at a floating rate per year equal to the 3-Month U.S. dollar London Interbank Offered Rate (“3-Month LIBOR”), reset quarterly,
plus 0.360% (the “Spread”), as described below. Interest will accrue from July 14, 2011 or from the most recent Interest Payment Date to which interest has been paid or duly provided for, as the case may be. Interest is payable
quarterly, in arrears, on January 14, April 14, July 14, and October 14 of each year, subject to the Business Day Convention (each, an “Interest Payment Date”), commencing on October 14, 2011 to the
Person in whose name the Notes were registered at the close 

  
 - 7 -

 
of business on the Regular Record Date immediately preceding the applicable Interest Payment Date, whether or not such day is a Business Day, until the principal thereof is paid or made available
for payment. 
 If the date of maturity of principal of the Notes or the date fixed for redemption or payment in connection with
an acceleration of any Note is not a Business Day, then payment of interest or principal need not be made on such date, but may be made on the next succeeding Business Day with the same force and effect as if made on the date of maturity or the date
fixed for redemption or payment in connection with acceleration, and no interest shall accrue as a result of the delayed payment. 
 The interest rate on the Notes for the first Interest Period will be 3-Month LIBOR, as determined on July 12, 2011 (treating July 12, 2011 as if it were an Interest Determination Date and
July 14, 2011 as the related Interest Reset Date), plus the Spread. Thereafter, the interest rate on the Notes for any Interest Period will be 3-Month LIBOR, as determined on the applicable Interest Determination Date, plus the Spread. The
interest rate on the Notes will be reset quarterly on each Interest Reset Date. For each Interest Period, interest on the Notes will be calculated on the basis of the actual number of days in the Interest Period divided by 360. 

The Calculation Agent will determine 3-Month LIBOR in accordance with the following provisions: With respect to any Interest
Determination Date, 3-Month LIBOR will be the rate for deposits in U.S. dollars having a maturity of three months commencing on the related Interest Reset Date that appears on the designated LIBOR page as of 11:00 a.m., London time, on that Interest
Determination Date. If no rate appears, 3-Month LIBOR, in respect of that Interest Determination Date, will be determined as follows: the Calculation Agent will request the principal London offices of each of four major reference banks in the London
interbank market, as selected by the Calculation Agent (after consultation with the Company), to provide the Calculation Agent with its offered quotation for deposits in U.S. dollars for the period of three months, commencing on the Interest Reset
Date, to prime banks in the London interbank market at approximately 11:00 a.m., London time, on that Interest Determination Date and in a principal amount that is representative for a single transaction in U.S. dollars in that market at that time.
If at least two quotations are provided, then 3-Month LIBOR on that Interest Determination Date will be the arithmetic mean of those quotations. If fewer than two quotations are provided, then 3-Month LIBOR on the Interest Determination Date will be
the arithmetic mean of the rates quoted at approximately 11:00 a.m., New York City time, on the Interest Determination Date by three major banks in The City of New York selected by the Calculation Agent (after consultation with the Company) for
loans in U.S. dollars to leading European banks, having a three-month maturity and in a principal amount that is representative for a single transaction in U.S. dollars in that market at that time; provided, however, that if the banks selected by
the Calculation Agent are not providing quotations in the manner described by this sentence, 3-Month LIBOR determined as of that Interest Determination Date will be 3-Month LIBOR in 

  
 - 8 -

 
effect on that Interest Determination Date. The designated LIBOR page is the Reuters screen “LIBOR01”, or any successor service for the purpose of displaying the London interbank rates
of major banks for U.S. dollars. The Reuters screen “LIBOR01” is the display designated as the Reuters screen “LIBOR01”, or such other page as may replace the Reuters screen “LIBOR01” on that service or such other
service or services as may be denominated by the British Bankers’ Association for the purpose of displaying London interbank offered rates for U.S. dollar deposits. 
 All calculations made by the Calculation Agent for the purposes of calculating the interest rate on the Notes shall be conclusive and binding on the Holders, the Company and the Trustee, absent manifest
error. 
 SECTION 2.04 Payment of Principal, Interest and Other Amounts. Payments of principal of, premium, if any, and
interest on the Notes shall be made in such coin or currency of the United States of America as at the time of payment is legal tender for payment of public and private debts and such payments on Notes represented by a Global Security shall be made
through one or more Paying Agents appointed under the Indenture to the Depositary or its nominee, as the Holder of the Global Security. Initially, the Paying Agent and Registrar for the Notes will be The Bank of New York Mellon Trust Company, N.A.,
in St. Louis, Missouri. The Company may change the Paying Agent or Registrar without prior notice to the Holders of the Notes, and in such an event the Company may act as Paying Agent or Registrar. Payments of principal of, premium, if any, and
interest on the Notes represented by a Global Security shall be made by wire transfer of immediately available funds; provided, however, that in the case of payments of principal and premium, if any, such Global Security is first
surrendered to the Paying Agent. 
 SECTION 2.05 Optional Tax Redemption. 

(a) The Company may, at the Company’s or the Parent Guarantor’s option, redeem the Notes in whole but not in part, upon not
less than thirty (30) nor more than sixty (60) days’ prior notice, at a redemption price equal to 100% of the principal amount of the Notes then outstanding plus accrued and unpaid interest on the principal amount being redeemed (and
all Additional Amounts, if any) to (but excluding) the Redemption Date, if (i) as a result of any change in, or amendment to, the laws, treaties, regulations or rulings of a jurisdiction in which the Company or any Guarantor is incorporated,
organized, or otherwise tax resident or any political subdivision or any authority thereof or therein having power to tax, or in the interpretation, application or administration of any such laws, treaties, regulations or rulings (including a
holding, judgment or order by a court of competent jurisdiction) which becomes effective on or after the Date of the Prospectus Supplement (any such change or amendment, a “Change in Tax Law”), the Company or, if a payment were then
due under a Guarantee, the relevant Guarantor, would be required to pay Additional Amounts and (ii) such obligation cannot be avoided by the Company or the relevant Guarantor taking 

  
 - 9 -

 
reasonable measures available to it; provided, however, that the Notes may not be redeemed to the extent such Additional Amounts arise solely as a result of the Company assigning its obligations
under the Notes to a Substitute Company (as defined in Section 801 of the Indenture), unless such assignment to a Substitute Company is undertaken as part of a plan of merger by the Parent Guarantor. 

(b) Prior to the mailing of any notice of redemption pursuant to this Section 2.05, the Company or the relevant Guarantor will
deliver to the Trustee an opinion of independent tax counsel of recognized standing to the effect that the Company or the relevant Guarantor is or would be obligated to pay such Additional Amounts as a result in such Change in Tax Law. 

(c) No notice of redemption pursuant to this Section 2.05 may be given earlier than ninety (90) days prior to the earliest date
on which the Company or the relevant Guarantor would be obligated to pay Additional Amounts if a payment in respect of the Notes were then due. 
 SECTION 2.06 Additional Covenant. Solely with respect to the Guarantees of the Notes by the Subsidiary Guarantors, clause (i) of Section 208 of the Indenture shall be deemed to read in
its entirety as follows: 
 “(i) at substantially the same time as its Guarantee of the Securities is terminated, the
relevant Guarantor is, or has been, released from its guarantee of the Senior Facility Agreement and the 2010 Senior Facility Agreement, or is no longer a guarantor under either the Senior Facility Agreement or the 2010 Senior Facility Agreement
and” 
 ARTICLE III 
 MISCELLANEOUS PROVISIONS 
 SECTION 3.01 Effectiveness. This
Twenty-Second Supplemental Indenture will become effective upon its execution and delivery. 
 SECTION 3.02 Original
Issue. The Notes may, upon execution of this Twenty-Second Supplemental Indenture, be executed by the Company and delivered by the Company and the Parent Guarantor to the Trustee for authentication, and the Trustee shall, upon Company order,
authenticate and deliver such Notes as in such Company order provided. 
 SECTION 3.03 Ratification and Integral Part.
The Indenture as supplemented by this Twenty-Second Supplemental Indenture, is in all respects ratified and confirmed, and this Twenty-Second Supplemental Indenture will be deemed an integral part of the Indenture in the manner and to the extent
herein and therein provided. 

  
 - 10 -

 SECTION 3.04 Priority. This Twenty-Second Supplemental Indenture shall be deemed part
of the Indenture in the manner and to the extent herein and therein provided. The provisions of this Twenty-Second Supplemental Indenture shall, subject to the terms hereof, supersede the provisions of the Indenture to the extent the Indenture is
inconsistent herewith. 
 SECTION 3.05 Successors and Assigns. All covenants and agreements in the Indenture, as
supplemented and amended by this Twenty-Second Supplemental Indenture, by the Company and the Guarantors will bind their respective successors and assigns, whether so expressed or not. 

SECTION 3.06 Counterparts. This Twenty-Second Supplemental Indenture may be executed in any number of counterparts, each of which
so executed shall be deemed to be an original, but all such counterparts shall together constitute but one and the same instrument. 
 SECTION 3.07 Guarantee Limitations. The limitations applicable to the Guarantees, as set forth in Section 209 of the Indenture and as amended by Section 2.01 of the Fifth Supplemental
Indenture, will apply to the Guarantees issued hereunder, provided that any further limitations, or any amendments or modifications to such Guarantees or limitations thereon, shall be set forth in an additional supplemental indenture, in each case
in accordance with the Indenture. 
 SECTION 3.08 The Trustee. The Trustee shall not be responsible in any manner
whatsoever for or in respect of the validity or sufficiency of this Twenty-Second Supplemental Indenture or for or in respect of the recitals contained herein, all of which are made solely by the Company and the Guarantors. 

SECTION 3.09 Governing Law. This Twenty-Second Supplemental Indenture and the Notes and Guarantees will be governed by and
construed in accordance with the laws of the State of New York. 

  
 - 11 -

 IN WITNESS WHEREOF, the parties hereto have caused this Twenty-Second Supplemental Indenture
to be duly executed, all as of the day and year first above written. 
  

			
	 ANHEUSER-BUSCH INBEV WORLDWIDE
INC.
 as Company

		
	By:	 	 /s/ Scott Gray

		 	Name: Scott Gray
		 	Title: Authorized Officer
	
	 ANHEUSER-BUSCH INBEV NV/SA

as Parent Guarantor

		
	By:	 	 /s/ Scott Gray

		 	Name: Scott Gray
		 	Title: Authorized Officer
		
	By:	 	 /s/ Christina Frank

		 	Name: Christina Frank
		 	Title: Authorized Officer
	
	 THE BANK OF NEW YORK MELLON
TRUST COMPANY, N.A.,
 as Trustee

		
	By:	 	 /s/ Kerry A. McFarland

		 	Name: Kerry A. McFarland
		 	Title: Vice President

 
			
	 ANHEUSER-BUSCH COMPANIES, INC.

As Subsidiary Guarantor

		
	By:	 	 /s/ Scott Gray

		 	Name: Scott Gray
		 	Title: Authorized Officer
	
	 BRANDBREW S.A.
 a société anonyme with its registered address at 5, Parc d’Activité Syrdall, L-5365 Luxembourg and registered with the Luxembourg register of commerce and companies under
number B-75696,
 as Subsidiary Guarantor

		
	By:	 	 /s/ Scott Gray

		 	Name: Scott Gray
		 	Title: Authorized Officer
	
	 COBREW NV/SA
 as Subsidiary Guarantor

		
	By:	 	 /s/ Scott Gray

		 	Name: Scott Gray
		 	Title: Authorized Officer

 Exhibit A 
 FORM OF NOTES 
 FACE OF SECURITY 

THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE
NAME OF A DEPOSITARY OR A NOMINEE THEREOF. THIS SECURITY MAY NOT BE EXCHANGED IN WHOLE OR IN PART FOR A SECURITY REGISTERED, AND NO TRANSFER OF THIS SECURITY IN WHOLE OR IN PART MAY BE REGISTERED, IN THE NAME OF ANY PERSON OTHER THAN SUCH DEPOSITARY
OR A NOMINEE THEREOF, EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE. 
 UNLESS THIS CERTIFICATE
IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”), TO ANHEUSER-BUSCH INBEV WORLDWIDE INC. OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED
IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF
DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN. 

  
 A-1

 Exhibit A 

 

 Anheuser-Busch InBev Worldwide Inc. 

Floating Rate Note due 2014 
 Payment of Principal, Premium, if any, 
 and Interest Irrevocably, Fully and
Unconditionally Guaranteed by 
 Anheuser-Busch InBev NV/SA, Anheuser-Busch Companies, Inc., BrandBrew S.A. and 

Cobrew NV/SA 
  

			
	No.             	  	USD             
		
	CUSIP No. 03523T BK3	  	ISIN: US03523TBK34

 Anheuser-Busch InBev Worldwide Inc., a corporation duly organized and existing under the
laws of the State of Delaware (herein called the “Company”, which term includes any successor Person under the Indenture hereinafter referred to), for value received, hereby promises to pay to Cede & Co., or its registered
assigns, on July 14, 2014 (the “Maturity Date”), the principal sum of USD –, and to pay interest thereon from July 14, 2011 or from the most recent Interest Payment Date to which interest has been paid or duly
provided for, quarterly, in arrears, on January 14, April 14, July 14, and October 14, subject to the Business Day Convention, in each year, commencing on October 14, 2011, at a floating rate equal to 3-Month
LIBOR, reset quarterly, plus 0.360%, per annum, as described below, until the principal hereof is paid or made available for payment. 
 The interest rate on the Notes for the first Interest Period will be 3-Month LIBOR, as determined on July 12, 2011 (treating July 12, 2011 as if it were an Interest Determination Date and
July 14, 2011 as the related Interest Reset Date), plus the Spread. Thereafter, the interest rate on the Notes for any Interest Period will be 3-Month LIBOR, as determined on the applicable Interest Determination Date, plus the Spread. The
interest rate on the Notes will be reset quarterly on each Interest Reset Date. For each Interest Period, interest on the Notes will be calculated on the basis of the actual number of days in the Interest Period divided by 360. 

The Calculation Agent will determine 3-Month LIBOR in accordance with the following provisions: With respect to any
Interest Determination Date, 3-Month LIBOR will be the rate for deposits in U.S. dollars having a maturity of three months commencing on the related Interest Reset Date that appears on the designated LIBOR page as of 11:00 a.m., London time, on that
Interest Determination Date. If no rate appears, 3-Month LIBOR, in respect of that Interest Determination Date, will be determined as follows: the Calculation Agent will request the principal London offices of each of four major reference banks in
the London interbank market, as selected by the Calculation Agent (after consultation with the Company), to provide the Calculation Agent with its offered quotation for deposits in U.S. dollars for the period of three months, commencing on the
Interest Reset Date, to prime banks in the London interbank market at approximately 11:00 a.m., London time, on that Interest Determination Date 

  
 A-2

 Exhibit A 

 

 
and in a principal amount that is representative for a single transaction in U.S. dollars in that market at that time. If at least two quotations are provided, then 3-Month LIBOR on that Interest
Determination Date will be the arithmetic mean of those quotations. If fewer than two quotations are provided, then 3-Month LIBOR on the Interest Determination Date will be the arithmetic mean of the rates quoted at approximately 11:00 a.m., New
York City time, on the Interest Determination Date by three major banks in The City of New York selected by the Calculation Agent (after consultation with the Company) for loans in U.S. dollars to leading European banks, having a three-month
maturity and in a principal amount that is representative for a single transaction in U.S. dollars in that market at that time; provided, however, that if the banks selected by the Calculation Agent are not providing quotations in the manner
described by this sentence, 3-Month LIBOR determined as of that Interest Determination Date will be 3-Month LIBOR in effect on that Interest Determination Date. The designated LIBOR page is the Reuters screen “LIBOR01”, or any successor
service for the purpose of displaying the London interbank rates of major banks for U.S. dollars. The Reuters screen “LIBOR01” is the display designated as the Reuters screen “LIBOR01”, or such other page as may replace the
Reuters screen “LIBOR01” on that service or such other service or services as may be denominated by the British Bankers’ Association for the purpose of displaying London interbank offered rates for U.S. dollar deposits. 

All calculations made by the Calculation Agent for the purposes of calculating the interest rate on the Notes shall be
conclusive and binding on the Holders, the Company and the Trustee, absent manifest error. 
 The interest so
payable, and punctually paid or duly provided for on any Interest Payment Date will, as provided in the Indenture, be paid to the Person in whose name this Security (or one or more Predecessor Securities) is registered at the close of business on
Regular Record Date for such interest, which shall be the fifteenth calendar day immediately preceding the applicable Interest Payment Date, whether or not such day is a Business Day. Any such interest not so punctually paid or duly provided for
will forthwith cease to be payable to the Holder on such Regular Record Date and may either be paid to the Person in whose name this Security (or one or more Predecessor Securities) is registered at the close of business on a Special Record Date for
the payment of such Defaulted Interest to be fixed by the Trustee, notice whereof shall be given to Holders of Securities of this series not less than 10 days prior to such Special Record Date, or be paid at any time in any other lawful manner not
inconsistent with the requirements of any securities exchange on which the Securities of this series may be listed, and upon such notice as may be required by such exchange, all as more fully provided in the Indenture. 

Subject to the terms of the Indenture, this Security is fully and unconditionally guaranteed as to all payments due
hereon whether at the Stated Maturity, by acceleration, redemption, repayment or otherwise in accordance with the terms of the Guarantees and the Indenture. 

  
 A-3

 Exhibit A 

 

 Payments of principal of, premium, if any, and interest on the Notes
shall be made in such coin or currency of the United States of America as at the time of payment is legal tender for payment of public and private debts and such payments on Notes represented by a Global Security shall be made through one or more
Paying Agents appointed under the Indenture to the Depositary or its nominee, as the Holder of this Security. Initially, the Paying Agent and Registrar for the Securities will be The Bank of New York Mellon Trust Company, N.A., St. Louis, Missouri.
The Company may change the Paying Agent or Registrar without prior notice to the Holders, and in such an event the Company may act as Paying Agent or Registrar. Payments of principal, premium, if any, and interest on the Securities represented by
this Security shall be made by wire transfer of immediately available funds; provided, however, that in the case of payments of principal and premium, if any, such Global Security is first surrendered to the Paying Agent. 

Notwithstanding any provision of this Security or the Indenture, the Company may make any and all payments of principal,
premium (if any) and interest on this Security pursuant to the applicable procedures of the Depositary for this Security as permitted in the Indenture. 
 Reference is hereby made to the further provisions of this Security set forth on the reverse hereof, which further provisions shall for all purposes have the same effect as if set forth at this place.

 Unless the certificate of authentication hereon has been executed by the Trustee referred to on the reverse
hereof by manual signature, this Security shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose. 

  
 A-4

 Exhibit A 

 

 IN WITNESS WHEREOF, the
Company has caused this instrument to be duly executed. 
 Dated: 

 

			
	ANHEUSER-BUSCH INBEV WORLDWIDE INC.
		
	By	 	  

		 	Name:
		 	Title:

  

	
	Attest:
	
	  

 CERTIFICATE OF AUTHENTICATION 

This Security is one of the Securities of the series designated herein and referred to in the within-mentioned Indenture.

  

			
	THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee
		
	By	 	  

		 	Authorized Signatory

  
 A-5

 Exhibit A 

 

 REVERSE OF SECURITY 

1. Securities and Indenture 
 This Security is one of a duly authorized issue of securities of the Company (payable in U.S. dollars) (herein called the “Securities”), issued and to be issued in one or more series
under an Indenture, dated as of October 16, 2009, as amended from time to time (the “Base Indenture”), as supplemented by the Twenty-Second Supplemental Indenture, dated as of July 14, 2011 (the “Twenty-Second
Supplemental Indenture” and together with the Base Indenture, the “Indenture”), in each case among the Company, Anheuser-Busch InBev NV/SA, as Parent Guarantor, the Subsidiary Guarantors party thereto from time to time and
The Bank of New York Mellon Trust Company, N.A., as Trustee (herein called the “Trustee”, which term includes any successor trustee under the Base Indenture), and reference is hereby made to the Indenture for a statement of the
respective rights, limitations of rights, duties and immunities thereunder of the Company, the Guarantors, the Trustee and the Holders of the Securities and of the terms upon which the Securities are, and are to be, authenticated and delivered.

 2. Series and Denomination 
 This Security is one of the series designated on the face hereof, initially limited to an aggregate principal amount of USD 300,000,000, except as provided in the Indenture. References herein to
“this series” mean the series of securities designated on the face hereof. Except as provided in the preceding paragraph, references herein to the “Securities” means (unless the context otherwise requires) the Securities
of this series and includes any other securities issued, as provided in the Indenture and forming a single series with the Securities of this series. 
 The Securities are issuable only in registered form without coupons in denominations of USD 1,000 in principal amount and integral multiples of USD 1,000 in excess thereof. 

3. Optional Tax Redemption 
 The Company may, at the Company’s or the Parent Guarantor’s option, redeem the Securities in whole, but not in part, upon not less than thirty (30) nor more than sixty (60) days’
prior notice, at a redemption price equal to 100% of the principal amount of the Securities then outstanding plus accrued and unpaid interest on the principal amount being redeemed (and all Additional Amounts, if any) to (but excluding) the
Redemption Date, if (i) as a result of any change in, or amendment to, the laws, treaties, regulations or rulings of a jurisdiction in which the Company or any Guarantor is incorporated, organized, or otherwise tax resident or any political
subdivision or any authority thereof or therein having power to tax, or in the interpretation, application or administration of any such laws, treaties, regulations or rulings (including a holding, judgment or order by a court of competent
jurisdiction) which becomes effective on or after the Date of the Prospectus Supplement (any such change or amendment, a “Change in Tax Law”), the 

  
 A-6

 Exhibit A 

 

 
Company or, if a payment were then due under a Guarantee, the relevant Guarantor, would be required to pay Additional Amounts and (ii) such obligation cannot be avoided by the Company or the
relevant Guarantor taking reasonable measures available to it; provided, however, that the Securities may not be redeemed to the extent such Additional Amounts arise solely as a result of the Company assigning its obligations under the Securities to
a Substitute Company, unless such assignment to a Substitute Company is undertaken as part of a plan of merger by the Parent Guarantor. 
 Prior to the mailing of any notice of redemption pursuant to this Section, the Company or the relevant Guarantor will deliver to the Trustee an opinion of independent tax counsel of recognized standing to
the effect that the Company or the relevant Guarantor is or would be obligated to pay such Additional Amounts as a result in such Change in Tax Law. 
 No notice of redemption pursuant to this Section may be given earlier that ninety (90) days prior to the earliest date on which the Company or the relevant Guarantor would be obligated to pay
Additional Amounts if a payment in respect of the Securities were then due. 
 4. Additional Amounts 

In the event that any Guarantor becomes obligated to make payments in respect of the Securities, such Guarantor will make
all payments in respect of the Securities without withholding or deduction for or on account of any present or future taxes or duties of whatever nature imposed or levied by way of withholding or deduction at source by or on behalf of any
jurisdiction in which such Guarantor is incorporated, organized, or otherwise tax resident or any political subdivision or any authority thereof or therein having power to tax (the “Relevant Taxing Jurisdiction”) unless such
withholding or deduction is required by law. In such event, such Guarantor will pay to the Holders such additional amounts (the “Additional Amounts”) as shall be necessary in order that the net amounts received by the Holders, after
such withholding or deduction, shall equal the respective amounts of principal and interest which would otherwise have been receivable in the absence of such withholding or deduction; except that no such Additional Amounts shall be payable on
account of any taxes or duties which: 
 (a) are payable by any person acting as custodian bank or collecting
agent on behalf of a Holder, or otherwise in any manner which does not constitute a deduction or withholding by such Guarantor from payment of principal or interest made by it, or 

(b) are payable by reason of the Holder or beneficial owner having, or having had, some personal or business connection
with such Relevant Taxing Jurisdiction and not merely by reason of the fact that payments in respect of the Securities or the Guarantees are, or for purposes of taxation are deemed to be, derived from sources in, or are secured in the Relevant
Taxing Jurisdiction, or 

  
 A-7

 Exhibit A 

 

 (c) are imposed or withheld by reason of the failure of the Holder or
beneficial owner to provide certification, information, documents or other evidence concerning the nationality, residence, or identity of the Holder and beneficial owner or to make any valid or timely declaration or similar claim or satisfy any
other reporting requirements relating to such matters, whether required or imposed by statute, treaty, regulation or administrative practice, as a precondition to exemption from, or a reduction in the rate of withholding or deduction of such taxes,
or 
 (d) consist of any estate, inheritance, gift, sales, excise, transfer, personal property or similar taxes,
or 
 (e) are imposed on or with respect to any payment by the applicable Guarantor to the registered Holder if
such Holder is a fiduciary or partnership or any person other than the sole beneficial owner of such payment to the extent that taxes would not have been imposed on such payment had such registered Holder been the sole beneficial owner of this
Security, or 
 (f) are deducted or withheld pursuant to (i) any European Union directive or regulation
concerning the taxation of interest income, or (ii) any international treaty or understanding relating to such taxation and to which the Relevant Taxing Jurisdiction or the European Union is a party, or (iii) any provision of law
implementing, or complying with, or introduced to conform with, such directive, regulation, treaty or understanding, or 
 (g) are payable by reason of a change in law or practice that becomes effective more than 30 days after the relevant payment of principal or interest becomes due, or is duly provided for and written
notice thereof is provided to the Holders, whichever occurs later, or 
 (h) are payable because any Security was
presented to a particular paying agent for payment if the Security could have been presented to another paying agent without any such withholding or deduction, or 

(i) are payable for any combination of (a) through (h) above. 

References to principal or interest in respect of the Securities shall be deemed to include any Additional Amounts which may be payable
as set forth in the Indenture. 
 The covenant regarding Additional Amounts shall not apply to any Guarantor at any time when
such Guarantor is incorporated in a jurisdiction in the United States, and will apply to the Company any time it is incorporated in a jurisdiction outside of the United States. 

  
 A-8

 Exhibit A 

 

 5. Transfer and Exchange 

As provided in the Indenture and subject to certain limitations therein set forth, the transfer of this Security is
registrable in the Security Register, upon surrender of this Security for registration of transfer at the office or agency of the Company in any place where the principal of and any premium and interest on this Security are payable, duly endorsed
by, or accompanied by a written instrument of transfer in form satisfactory to the Company and the Security Registrar duly executed by, the Holder hereof or his attorney duly authorized in writing, and thereupon one or more new Securities of this
series and of like tenor, of authorized denominations and for the same aggregate principal amount, will be issued to the designated transferee or transferees. 
 As provided in the Indenture and subject to certain limitations therein set forth, Securities of this series are exchangeable for a like aggregate principal amount of Securities of this series and of like
tenor of a different authorized denomination, as requested by the Holder surrendering the same. 
 No service
charge shall be made for any such registration of transfer or exchange, but the Company may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection therewith. 

Prior to due presentment of this Security for registration of transfer, the Company, the Guarantors, the Trustee and any
agent of the Company, the Guarantors or the Trustee may treat the Person in whose name this Security is registered as the owner hereof for all purposes, whether or not this Security be overdue, and neither the Company, the Guarantors, the Trustee
nor any such agent shall be affected by notice to the contrary. 
 6. Limitation on Suits 

As provided in and subject to the provisions of the Indenture, the Holder of this Security shall not have the right to
institute any proceeding with respect to the Indenture or for the appointment of a receiver or trustee or for any other remedy thereunder, unless such Holder shall have previously given the Trustee written notice of a continuing Event of Default
with respect to the Securities of this series, the Holders of not less than 25% in principal amount of the Securities of this series at the time Outstanding shall have made written request to the Trustee to institute proceedings in respect of such
Event of Default as Trustee and offered the Trustee indemnity and/or security, and the Trustee shall not have received from the Holders of a majority in principal amount of Securities of this series at the time Outstanding a direction inconsistent
with such request, and shall have failed to institute any such proceeding, for 60 days after receipt of such notice, request and offer of indemnity and/or security. The foregoing shall not apply to any suit instituted by the Holder of this Security
for the enforcement of any payment of principal hereof or any premium or interest hereon on or after the respective due dates expressed herein. 
 No reference herein to the Indenture and no provision of this Security or of the Indenture shall alter or impair the obligation of the Company, which is absolute and unconditional, to pay the principal of
and any premium and interest on this Security at the times, place and rate, and in the coin or currency, herein prescribed. 

  
 A-9

 Exhibit A 

 

 7. Amendment, Modification and Waiver 

The Indenture permits, with certain exceptions as therein provided, the amendment thereof and the modification of the
rights and obligations of the Company or the Guarantors and the rights of the Holders of the Securities of each series to be affected under the Indenture at any time by the Company and the Trustee with the consent of the Holders of a majority in
principal amount of the Securities at the time Outstanding (irrespective of series) that are to be affected. The Indenture also contains provisions permitting the Holders of specified percentages in principal amount of the Securities of each series
at the time Outstanding, on behalf of the Holders of all Securities of such series, to waive compliance by the Company and the Guarantors with certain provisions of the Indenture and certain past defaults under the Indenture and their consequences.
Any such consent or waiver by the Holder of this Security shall be conclusive and binding upon such Holder and upon all future Holders of this Security and of any Security issued upon the registration of transfer hereof or in exchange herefor or in
lieu hereof, whether or not notation of such consent or waiver is made upon this Security. 
 8. Defeasance 

The Indenture contains provisions for defeasance at any time of certain restrictive covenants and Events of Default with
respect to this Security upon compliance with certain conditions set forth in the Indenture. 
 9. Governing Law

 This Security shall be governed by and construed in accordance with the laws of the State of New York.

 10. Defined Terms 
 All terms used in this Security which are defined in the Base Indenture or the Twenty-Second Supplemental Indenture, shall have the meanings assigned to them in the Base Indenture or the Twenty-Second
Supplemental Indenture. 

  
 A-10

 Exhibit B 

 

 FORM OF GUARANTEE 

For value received, the undersigned (herein called the “Guarantors”, and each, a “Guarantor” which
terms include any successor Person or Persons under the Indenture referred to in the Security upon which this Guarantee is endorsed), hereby jointly and severally, irrevocably, fully and unconditionally guarantee to each Holder of this Security,
which has been authenticated and delivered by the Trustee, the due and punctual payment of the principal of (including any amount in respect of original issue discount), and any premium and interest (together with any Additional Amounts payable
pursuant to the terms of this Security), on this Security and the due and punctual payment of the sinking fund payments, if any, and analogous obligations, if any, provided for pursuant to the terms of this Security, when and as the same shall
become due and payable, whether at Stated Maturity or upon redemption or upon declaration of acceleration or otherwise according to the terms of this Security and of the Indenture. In case of default by the Company in the payment of any such
principal (including any amount in respect of original issue discount), interest (together with any Additional Amounts payable pursuant to the terms of this Security), sinking fund payment, or analogous obligation, each Guarantor agrees duly and
punctually to pay the same. Each Guarantor hereby agrees that its obligations hereunder shall rank pari passu with all other unsecured and unsubordinated obligations of such Guarantor, shall be as principal and not merely as surety, and shall
be absolute and unconditional irrespective of any extension of the time for payment of this Security, any modification of this Security, any invalidity, irregularity or unenforceability of this Security or the Indenture, any failure to enforce the
same or any waiver, modification, consent or indulgence granted to the Company with respect thereto by the Holder of this Security or the Trustee, or any other circumstances which may otherwise constitute a legal or equitable discharge of a surety
or guarantor. Each Guarantor hereby waives diligence, presentment, demand of payment, filing of claims with a court in the event of merger or bankruptcy of the Company, any right to require a demand or proceeding first against the Company, protest
or notice with respect to this Security or the indebtedness evidenced thereby and all demands whatsoever, and covenants that this Guarantee will not be discharged as to this Security except by payment in full of the principal of (including any
amount payable in respect of original issue discount), and any premium and interest (together with any Additional Amounts payable pursuant to the terms of this Security), thereon. 

Each Guarantor irrevocably waives any and all rights to which it may be entitled, by operation of law or otherwise, upon
making any payment hereunder (i) to be subrogated to the rights of a Holder against the Company with respect to such payment or otherwise to be reimbursed, indemnified or exonerated by the Company in respect thereof or (ii) to receive any
payment, in the nature of contribution or for any other reason, from any other obligor with respect to such payment. 
 This Guarantee shall not be valid or become obligatory for any purpose with respect to this Security until the certificate of authentication on this Security shall have been signed by the Trustee.

  
 B-1

 Exhibit B 

 

 All terms used in this Guarantee which are not defined herein shall have
the meaning assigned to them in the Security upon which this Guarantee is endorsed. 
 This Guarantee is subject
to the release upon the terms set forth in the Indenture. 
 This Guarantee is subject to certain limitations
and waivers set forth in the Indenture, as it may be supplemented from time to time. 
 This Guarantee is
governed by and construed in accordance with the laws of the State of New York. 
 IN WITNESS WHEREOF, each of
the undersigned has caused this Guarantee to be signed by facsimile by its duly authorized officer or representative and, if required by applicable law, has caused a facsimile of its corporate seal to be affixed hereunto or imprinted hereon.

  

					
	 ANHEUSER-BUSCH INBEV NV/SA

as Parent Guarantor

		
	By:	 	  

		 	Name:	 	
		 	Title:	 	Authorized Officer
		
	By:	 	  

		 	Name:	 	
		 	Title:	 	Authorized Officer
	
	 ANHEUSER-BUSCH COMPANIES, INC.

As Subsidiary Guarantor

		
	By:	 	  

		 	Name:	 	
		 	Title:	 	Authorized Officer

  
 B-2

 Exhibit B 

 

 
					
	 BRANDBREW S.A.
 a société anonyme with its registered address at 5, Parc d’Activité Syrdall, L-5365 Luxembourg and registered with the Luxembourg register of commerce and companies under
number B-75696,
 as Subsidiary Guarantor

		
	By:	 	  

		 	Name:	 	
		 	Title:	 	Authorized Officer
	
	 COBREW NV/SA
 as Subsidiary Guarantor

		
	By:	 	  

		 	Name:	 	
		 	Title:	 	Authorized Officer

  
 B-3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00192-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00192-of-00352.parquet"}]]